Traws Pharma Inc. (TRAW)
NASDAQ: TRAWHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
TRAW stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.38M
- EPS (TTM)
- -$1.71
- Dividend yield
- None
- 52-week range
- 0.43 – 3.27
- Day range
- 0.4622 – 0.4806
- Volume / Avg
- 99.48K / 569.02K
- Beta
- —
- Shares outstanding
- 15.37M
52-week range
TRAW stock today
Shares of Traws Pharma (TRAW) finished higher on Oct 8 at $0.4803, a gain of 0.27% or $0.0013 per share, versus the S&P 500's 0.47% decline. Trading was light, with 99.48K shares changing hands, about 17% of the average daily volume. At this level, TRAW sits near the bottom of its 52-week range of $0.43 to $3.27: 85.3% below the high and 11.7% above the low.
Traws Pharma has posted a net loss over the last twelve months (EPS of -$1.71), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Traws Pharma
Company profileTraws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Iain D. Dukes DPHIL, M.A., Ph.D.
- Headquarters
- Newtown, PA
- Employees
- 4
- IPO year
- 2013
- Website
- trawspharma.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$1.00+108.20%
- Strong buy 0
- Buy 0
- Hold 2
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Traws Pharma peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SKYESkye Bioscience Inc. | 1.68 | +1.82% | $7.44M | vs TRAW |
| CURXCuranex Pharmaceuticals Inc | 4.76 | -0.94% | $7.46M | vs TRAW |
| CLGNCollPlant Biotechnologies Ltd | 3.97 | +14.74% | $7.51M | vs TRAW |
| SNGXSoligenix Inc. | 0.3466 | -1.95% | $7.54M | vs TRAW |
| LGVNLongeveron Inc. Class A | 2.37 | -2.87% | $7.56M | vs TRAW |
| AIMAIM ImmunoTech Inc. | 0.1796 | -1.75% | $7.17M | vs TRAW |
| BOLTBolt Biotherapeutics Inc. | 3.65 | +1.39% | $7.03M | vs TRAW |
| APREAprea Therapeutics Inc. | 0.5582 | -7.74% | $7.03M | vs TRAW |
Indexes, lists and sector
Appears in lists
Traws Pharma stock FAQ
What is Traws Pharma's stock price today?
TRAW last traded at $0.4803 as of Oct 8, 4:00 PM EDT, up 0.27% on the day. Prices are delayed at least 15 minutes.
Who is Traws Pharma's CEO?
Dr. Iain D. Dukes DPHIL, M.A., Ph.D. is the chief executive officer of Traws Pharma Inc., which has about 4 employees.
What is the TRAW 52-week high?
The 52-week high for TRAW is $3.27 and the 52-week low is $0.43. The stock is currently 85.3% below its high.